Lipicare Pharmaceuticals
Eye Drops in Micro-emulsion Technology
Company Overview
Snapshot
Founded in June 2016 by Rafael Ezra, Lipicare Pharmaceuticals operates with 1–10 employees. The company has secured funding across one round, with BIOLIGHT Life Sciences participating as an investor. In July 2021, Lipicare Pharmaceuticals entered into a manufacturing and distribution agreement in Europe for its product designed to alleviate symptoms of screen exposure syndrome.
Business overview
Lipicare Pharmaceuticals specializes in developing products based on nano-emulsions of phospholipids, designed to effectively and comfortably deliver fatty medications to the ocular surface. The company's core product, Ocular D, is an eye drop for treating dry eyes, which integrates vitamin D and has shown potential to block blue light radiation. Lipicare Pharmaceuticals serves the healthcare and life sciences sectors, focusing on ophthalmology and drug delivery, with a B2B2C and B2B business model, primarily targeting the European market.
Strategic signal
In July 2021, Lipicare Pharmaceuticals secured a manufacturing and distribution agreement in Europe for its product addressing screen exposure syndrome. This agreement signals significant progress in commercialization and market entry for the company's ocular health solutions, indicating a strategic move towards broader European market penetration and validation of its nano-emulsion technology.
Log in to access full profile ›Company Intelligence Q&A
- What is Lipicare Pharmaceuticals' primary focus?
- Lipicare Pharmaceuticals focuses on developing products based on nano-emulsions of phospholipids for effective and comfortable delivery of fatty medications to the ocular surface.
- What is Ocular D?
- Ocular D is Lipicare Pharmaceuticals' first commercial product, designed to treat dryness in the eye with integrated vitamin D. Laboratory testing has also shown it helps block blue light radiation.
- When was Lipicare Pharmaceuticals founded?
- Lipicare Pharmaceuticals was founded in June 2016.
- Which investor participated in Lipicare Pharmaceuticals' funding round?
- In December 2019, Lipicare Pharmaceuticals received funding from BIOLIGHT Life Sciences.
- What is the significance of the European manufacturing and distribution agreement?
- In July 2021, Lipicare Pharmaceuticals secured an agreement for manufacturing and distribution in Europe for its product addressing symptoms from screen exposure, indicating a strategic move towards commercialization and market entry in the region.